AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27791128 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with peptide 1
Number of subjects: 2
Study 27791128 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with peptide 1 or 7 in combination with RFASE
Number of subjects: 2
Study 27791128 — intervention group
Group type: COMPARATOR
Intervention: Antibodies raised with peptides 15 and 20
Number of subjects: 2
Study 27791347 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06651600 (JAK3-selective inhibitor)
Number of subjects: 0
Study 27791347 — intervention group
Group type: COMPARATOR
Intervention: JAK3-selective inhibition
Number of subjects: 0
Study 27792655 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected QT interval (QT)
Number of subjects: 93
Study 27792656 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel with PPI
Number of subjects: 11955
Study 27792656 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel with PPI
Number of subjects: 11955
Study 27792656 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel without PPI
Number of subjects: 11955
Study 27792656 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel without PPI
Number of subjects: 11955
Study 27792656 — intervention group
Group type: COMPARATOR
Intervention: PPI use
Number of subjects: 11955
Study 27792741 — intervention group
Group type: COMPARATOR
Intervention: TTR<65%
Number of subjects: 9934
Study 27792741 — intervention group
Group type: EXPERIMENTAL
Intervention: TTR≥65%
Number of subjects: 9934
Study 27793100 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose
Number of subjects: 427
Study 27793100 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 427
Study 27793100 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial glucose
Number of subjects: 427
Study 27793100 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose, postprandial glucose, and HbA1c
Number of subjects: 427
Study 27793105 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of regional cerebral saturation of oxygen using pediatric cerebral sensors
Number of subjects: 43
Study 27793105 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of mean arterial blood pressure (MAP) and pulse oximetry (SpO2)
Number of subjects: 43
Study 27793105 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestation as a possible risk factor
Number of subjects: 43
Study 27793162 — intervention group
Group type: EXPERIMENTAL
Intervention: iBreastExam (iBE) performed by a trained ultrasound technician
Number of subjects: 78
Study 27793162 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 78
Study 27793850 — intervention group
Group type: EXPERIMENTAL
Intervention: DMUC5754A (0.3-3.2 mg/kg every 3 weeks)
Number of subjects: 77
Study 27793850 — intervention group
Group type: EXPERIMENTAL
Intervention: DMUC5754A (0.8-1.6 mg/kg weekly)
Number of subjects: 77
Study 27793850 — intervention group
Group type: EXPERIMENTAL
Intervention: DMUC5754A (Q3W)
Number of subjects: 77
Study 27793850 — intervention group
Group type: EXPERIMENTAL
Intervention: DMUC5754A (Q1W)
Number of subjects: 77
Study 27793850 — intervention group
Group type: EXPERIMENTAL
Intervention: DMUC5754A
Number of subjects: 77
Study 27794402 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-A3
Number of subjects: 377
Study 27794402 — intervention group
Group type: EXPERIMENTAL
Intervention: PRAME
Number of subjects: 377
Study 27794402 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MAGE-A3 and PRAME
Number of subjects: 377
Study 27794402 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one TAA (MAGE-A3 or PRAME)
Number of subjects: 377
Study 27794402 — intervention group
Group type: EXPERIMENTAL
Intervention: Squamous cell carcinomas
Number of subjects: 377
Study 27794402 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 377
Study 27794406 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary palliative care intervention including care planning and education sessions for patients and FCGs
Number of subjects: 41
Study 27794406 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 41
Study 27795367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 6
Study 27795384 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 0
Study 27795384 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27795599 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Thoughts and Actions (PTA)
Number of subjects: 120
Study 27795599 — intervention group
Group type: COMPARATOR
Intervention: Individual Support Program (ISP)
Number of subjects: 120
Study 27796252 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimism
Number of subjects: 156
Study 27796252 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude
Number of subjects: 156
Study 27796540 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab monotherapy (10 or 20 mg/kg)
Number of subjects: 31
Study 27796740 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP0113 (5 mg, five doses at intervals before and after HCT)
Number of subjects: 10
Study 27796820 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI)
Number of subjects: 35
Study 27796820 — intervention group
Group type: COMPARATOR
Intervention: Choline-positron emission tomography-computed tomography (choline-PET/CT)
Number of subjects: 35
Study 27797317 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic workup for pulmonary embolism including low pretest clinical probability and negative d-dimer assay.
Number of subjects: 560
Study 27797317 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomographic pulmonary angiography or ventilation-perfusion lung scanning for patients without low pretest clinical probability and negative d-dimer assay.
Number of subjects: 560
Study 27797317 — intervention group
Group type: COMPARATOR
Intervention: Patients with alternative explanation for syncope.
Number of subjects: 560
Study 27797317 — intervention group
Group type: COMPARATOR
Intervention: Patients without alternative explanation for syncope.
Number of subjects: 560
Study 27797889 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained microalbuminuria
Number of subjects: 1441
Study 27797889 — intervention group
Group type: EXPERIMENTAL
Intervention: Remitted microalbuminuria
Number of subjects: 1441
Study 27797889 — intervention group
Group type: EXPERIMENTAL
Intervention: Macroalbuminuria
Number of subjects: 1441
Study 27797979 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker implantation for high-risk patients (≥70 ms HV interval)
Number of subjects: 200
Study 27797979 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop recorder device with remote monitoring for lower-risk patients (HV <70 ms)
Number of subjects: 200
Study 27797988 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-month physical activity programme combined with a normocaloric diet
Number of subjects: 68
Study 27797988 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-month physical activity programme
Number of subjects: 68
Study 27797988 — intervention group
Group type: EXPERIMENTAL
Intervention: Normocaloric diet
Number of subjects: 68
Study 27797988 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 68
Study 27797988 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of physical activity and normocaloric diet
Number of subjects: 68
Study 27798002 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants associated with CLBP
Number of subjects: 12000
Study 27798002 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycomics profiles associated with CLBP
Number of subjects: 12000
Study 27798002 — intervention group
Group type: EXPERIMENTAL
Intervention: Activomics profiles associated with CLBP
Number of subjects: 12000
Study 27798032 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy
Number of subjects: 3741
Study 27798339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation
Number of subjects: 39
Study 27798342 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharides (HMOs) concentration measurement using LC-mass spectrometry
Number of subjects: 133
Study 27798342 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretor milk samples from Malawi
Number of subjects: 133
Study 27798342 — intervention group
Group type: EXPERIMENTAL
Intervention: Fucosylated HMOs in secretor milk samples from Malawi
Number of subjects: 133
Study 27798346 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-fasting intervals (mean ± SD: 9.9 ± 1.6 h)
Number of subjects: 1061
Study 27798346 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily eating episodes (mean ± SD: 4.2 ± 1.3 times/d)
Number of subjects: 1061
Study 27798346 — intervention group
Group type: COMPARATOR
Intervention: Night-fasting intervals
Number of subjects: 1061
Study 27798346 — intervention group
Group type: COMPARATOR
Intervention: Daily eating episodes
Number of subjects: 1061
Study 27798550 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of TDF during labor (Cohort 1)
Number of subjects: 89
Study 27798550 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg dose on days 0, 3 and 5 (Cohort 2)
Number of subjects: 89
Study 27798550 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg maternal dose during labor, followed by 6 mg/kg infant dose on days 0, 3 and 5 (Cohort 3)
Number of subjects: 89
Study 27798550 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort of HIV-exposed infants
Number of subjects: 89
Study 27799048 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT in 23 fractions of 2 Gy and HDR in 3 fractions of 6.5 Gy
Number of subjects: 118
Study 27799138 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based injury prevention program with anticipatory guidance
Number of subjects: 308
Study 27799138 — intervention group
Group type: COMPARATOR
Intervention: Relevant booklet on parenting
Number of subjects: 308
Study 27799204 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg efavirenz (single oral dose)
Number of subjects: 73
Study 27799230 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel administration for 7 days
Number of subjects: 287
Study 27799506 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib and NovoTTF-100A (Tumor Treatment Fields device)
Number of subjects: 1
Study 27799506 — intervention group
Group type: COMPARATOR
Intervention: NovoTTF-100A (Tumor Treatment Fields device) with concurrent radiation and chemotherapy (CCRT)
Number of subjects: 1
Study 27799945 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a fixed dose of 0.033 mg/kg/day for 260 weeks
Number of subjects: 80
Study 27799945 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a fixed dose of 0.067 mg/kg/day for 260 weeks
Number of subjects: 80
Study 27799945 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (both doses)
Number of subjects: 80
Study 27799945 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (high dose)
Number of subjects: 80
Study 27799945 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 80
Study 27799945 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 80
Study 27800159 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management (CM)
Number of subjects: 0
Study 27801315 — intervention group
Group type: EXPERIMENTAL
Intervention: JAK inhibitor ruxolitinib
Number of subjects: 0
Study 27801983 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (most common type of glucocorticoid)
Number of subjects: 1166
Study 27801983 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone dosing frequency
Number of subjects: 1166
Study 27801983 — intervention group
Group type: EXPERIMENTAL
Intervention: Various regimens for hydrocortisone
Number of subjects: 1166
Study 27802497 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese participants with normoglycemia (n=5)
Number of subjects: 102
Study 27802497 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese participants with prediabetes (n=9)
Number of subjects: 102
Study 27802497 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese participants with diabetes (n=9)
Number of subjects: 102
Study 27802497 — intervention group
Group type: COMPARATOR
Intervention: Lean controls (n=2)
Number of subjects: 102
Study 27802497 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 102
Study 27802497 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 102
Study 27802497 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 102
Study 27802497 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 102
Study 27802546 — intervention group
Group type: EXPERIMENTAL
Intervention: Type VII collagen gene-corrected grafts (approximately 35 cm2) transplanted onto 6 wounds in each patient (n=24 grafts).
Number of subjects: 4
Study 27802546 — intervention group
Group type: EXPERIMENTAL
Intervention: Type VII collagen gene-corrected grafts.
Number of subjects: 4
Study 27803005 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg daily
Number of subjects: 18
Study 27803036 — intervention group
Group type: EXPERIMENTAL
Intervention: IMR>40
Number of subjects: 283
Study 27803036 — intervention group
Group type: COMPARATOR
Intervention: IMR>40 and CFR≤2.0
Number of subjects: 283
Study 27803138 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Golimumab (GOL) 50 mg or 100 mg every 4 weeks
Number of subjects: 2867
Study 27803138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2867
Study 27803655 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation at point ST36
Number of subjects: 0
Study 27803655 — intervention group
Group type: COMPARATOR
Intervention: Control point CP1 (same dermatome)
Number of subjects: 0
Study 27803655 — intervention group
Group type: COMPARATOR
Intervention: Control point CP2 (different dermatome)
Number of subjects: 0
Study 27803954 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral closure (Angio-Seal™, St. Jude Medical, Inc.)
Number of subjects: 400
Study 27803954 — intervention group
Group type: COMPARATOR
Intervention: Radial compression (TR Band)
Number of subjects: 400
Study 27805836 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor/Ivacaftor (200 mg lumacaftor/250 mg ivacaftor orally every 12 hours for 24 weeks)
Number of subjects: 58
Study 27805836 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor/Ivacaftor
Number of subjects: 58
Study 27806864 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward-based spatial learning task
Number of subjects: 27
Study 27806864 — intervention group
Group type: COMPARATOR
Intervention: Control condition (unexpected rewards)
Number of subjects: 27
Study 27806864 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning condition (expected rewards)
Number of subjects: 27
Study 27806964 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone protocol following S1P
Number of subjects: 32
Study 27806964 — intervention group
Group type: COMPARATOR
Intervention: Best clinical judgment prior to protocol implementation
Number of subjects: 32
Study 27806978 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition reference curves for preterm infants generated using air-displacement plethysmography (ADP) and lambda-mu-sigma method for percentile estimation.
Number of subjects: 223
Study 27806978 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition reference charts for total FM and FFM at birth in preterm infants.
Number of subjects: 223
Study 27807285 — intervention group
Group type: EXPERIMENTAL
Intervention: Verubecestat (MK-8931); chronic treatment in rats and monkeys
Number of subjects: 0
Study 27807285 — intervention group
Group type: EXPERIMENTAL
Intervention: Verubecestat (MK-8931); single and multiple doses in healthy human subjects and AD patients
Number of subjects: 0
Study 27807306 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0
Study 27807306 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 27809785 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis patients
Number of subjects: 30
Study 27809785 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 27809833 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral cataract extraction with intraocular lens implantation
Number of subjects: 53
Study 27810712 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnographic sleep parameters (PSG)
Number of subjects: 54
Study 27810720 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Index - a latent measure assessing impact of illness on functioning and QOL
Number of subjects: 0
Study 27810876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients (homozygotes and heterozygotes)
Number of subjects: 30
Study 27810876 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 30
Study 27810876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis homozygotes
Number of subjects: 30
Study 27810876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis heterozygotes
Number of subjects: 30
Study 27811070 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 µg
Number of subjects: 392
Study 27811070 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 µg
Number of subjects: 392
Study 27811070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 27811151 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography (CTA) alone in females
Number of subjects: 381
Study 27811151 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography (CTA) combined with myocardial perfusion imaging (CTP) in females
Number of subjects: 381
Study 27811151 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography (CTA) alone in males
Number of subjects: 381
Study 27811151 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography (CTA) combined with myocardial perfusion imaging (CTP) in males
Number of subjects: 381
Study 27811151 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental value of CTP over CTA alone in females
Number of subjects: 381
Study 27811151 — intervention group
Group type: COMPARATOR
Intervention: Prevalence of flow-limiting CAD in males
Number of subjects: 381
Study 27811151 — intervention group
Group type: COMPARATOR
Intervention: Prevalence of flow-limiting CAD in females
Number of subjects: 381
Study 27811203 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI concentration < limit of detection (LoD) at presentation in the derivation cohort
Number of subjects: 3845
Study 27811203 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI concentration < limit of detection (LoD) at presentation in the validation cohort
Number of subjects: 3845
Study 27811203 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI concentrations <99th percentile at presentation
Number of subjects: 3845
Study 27811504 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation after nephrectomy without adjuvant chemotherapy
Number of subjects: 116
Study 27812090 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Tests (RDTs)
Number of subjects: 0
Study 27812090 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical algorithms
Number of subjects: 0
Study 27812090 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and first-line laboratory features
Number of subjects: 0
Study 27812547 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled sodium nitrite at doses of 45 mg and 90 mg
Number of subjects: 36
Study 27812547 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled sodium nitrite
Number of subjects: 36
Study 27812547 — intervention group
Group type: COMPARATOR
Intervention: Inhaled nitric oxide
Number of subjects: 36
Study 27813195 — intervention group
Group type: EXPERIMENTAL
Intervention: D-mannose powder 1.5 grams twice daily for 16 weeks
Number of subjects: 22
Study 27814297 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]FDDNP PET
Number of subjects: 30
Study 27814297 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF Aβ levels
Number of subjects: 30
Study 27814297 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal assessment of [18F]FDDNP binding
Number of subjects: 30
Study 27814297 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF tau levels
Number of subjects: 30
Study 27814346 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 0.1% eye micro-drops
Number of subjects: 23
Study 27814377 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg of the homologous strain vaccine re-immunized at 6-months
Number of subjects: 0
Study 27814377 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg alum-adjuvanted clade 2, A/Indonesia vaccine re-immunized at 22-months
Number of subjects: 0
Study 27814377 — intervention group
Group type: COMPARATOR
Intervention: 30 μg alum-adjuvanted A/Vietnam vaccine
Number of subjects: 0
Study 27814457 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder patients (BD)
Number of subjects: 28
Study 27814457 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (HV)
Number of subjects: 28
Study 27814689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home residents
Number of subjects: 132
Study 27814689 — intervention group
Group type: COMPARATOR
Intervention: Nursing home staff
Number of subjects: 132
Study 27814689 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents without dementia
Number of subjects: 132
Study 27814689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home residents during outbreaks
Number of subjects: 132
Study 27814689 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ARI episodes
Number of subjects: 132
Study 27814689 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific viruses in residents
Number of subjects: 132
Study 27814689 — intervention group
Group type: COMPARATOR
Intervention: Specific viruses in staff
Number of subjects: 132
Study 27814689 — intervention group
Group type: EXPERIMENTAL
Intervention: Outbreak cases
Number of subjects: 132